EUCTR2013-001287-34-NL
Active, not recruiting
Phase 1
A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexisting beta-blocker therapy - Study to assess the safety of BAY 1067197 in stable heart failure patients using ß-blockers
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Heart failure
- Sponsor
- Bayer HealthCare AG
- Enrollment
- 11
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Stable systolic heart failure (heart failure with reduced ejection fraction, HFrEF; NYHA I\-III) in sinus rhythm with a documented EF \=45% within the last 3 months
- •Stable standard HF therapy including intermediate to high dose ß\-blocker with either \= 95 mg metoprolol succinate (controlled release tablet), \= 5mg Bisoprolol (IR\-tablet) or \=5mg Nebivolol (IR tablet) for at least 4 weeks. Additional intake of angiotensin\-converting enzyme (ACE) inhibitors or angiotensin receptor blockers and optional aldosterone\-receptor antagonists, diuretics or digitalis is allowed
- •Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate and a history of vasomotor symptoms) or women without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy (documented by medical report verification). Men enrolled in this study must agree to use adequate barrier birth control measures during the treatment period of the study and for 12 weeks after receiving the investigational medicinal product (IMP)
- •Male patients must agree not to act as sperm donor for 12 weeks after dosing
- •Age: 18 to 75 years (inclusive) at the first screening visit
- •Ethnicity: White
- •Body mass index (BMI): above/equal 18\.0 and below/equal 29\.9 kg/m²
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •Biventricular pacing/active CRT device
- •Dependency on pacemaker or ICD device with pacemaker dependency (a paced ventricular rhythm \> 5% of heart activity)
- •A history of relevant diseases of vital organs other than the heart, of the central nervous system or other organs
- •Known hypersensitivity to the study preparations (active substances or excipients of the preparations) or to any other ß\-blocker
- •Current or history of AV\-Block \> I°
- •Unstable condition, indicated by requirement of IV drug (diuretic, inotrope, etc.) or NYHA IV
- •Acute Coronary Syndrome (defined as unstable angina \[UA], non\-ST elevation myocardial infarction \[NSTEMI], ST elevation myocardial infarction \[STEMI]) within 3 months prior to first study drug administration
- •History of asthma or COPD \= GOLD II and/or allergic asthma
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexisting beta-blocker therapycongestive heart failureheart failure10019280NL-OMON38750Bayer10
Active, not recruiting
Not Applicable
Study comparing the effect on pain and function of an anaesthetic injection with a placebo (non-active substance) for the treatment of pain at the trapezius muscle.Trapezius muscle pain in patients with fibromyalgiaMedDRA version: 18.0Level: PTClassification code 10048439Term: FibromyalgiaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2015-000796-28-ESFundacio Clinic per a la Recerca Biomèdica
Active, not recruiting
Not Applicable
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - NAThis study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in line with Americian Association recommendations.MedDRA version: 8.1Level: LLTClassification code 10055026Term: Prostatic obstructionEUCTR2006-002055-32-DEPlethora Solutions Limited80
Active, not recruiting
Phase 1
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - PSD506-OAB-004benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS)MedDRA version: 8.1 Level: LLT Classification code 10055026 Term: Prostatic obstructionEUCTR2006-002055-32-IEPlethora Solutions Limited80
Active, not recruiting
Not Applicable
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - PSD506-OAB-004benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS)MedDRA version: 8.1Level: LLTClassification code 10055026Term: Prostatic obstructionEUCTR2006-002055-32-GBPlethora Solutions Limited80